Accelerate Diagnostics Inc. is teaming with BioCheck Inc. to fight the novel coronavirus with a collaboration to distribute antibody tests in the U.S. and abroad.
Tucson-based Accelerate Diagnostics announced the agreement on April 15 along with its preliminary first quarter financial results in a regulatory filing that showed net sales up in 2020 but warned of uncertainty for the future connected with the COVID-19 pandemic.
Shares of the company closed up 7.89%, or 66 cents, on Thursday to finish at $9.02.
The stock had reached $9.44 earlier in the day on the news of the COVID-19 testing deal.
